Lorrain Daniel S. 4
4 · Contineum Therapeutics, Inc. · Filed Apr 6, 2026
Research Summary
AI-generated summary of this filing
Contineum Therapeutics (CTNM) CSO Daniel Lorrain Sells 4,170 Shares
What Happened
Daniel S. Lorrain, Chief Scientific Officer of Contineum Therapeutics (CTNM), sold 4,170 shares on April 6, 2026. The weighted average sale price was $13.43 per share, generating gross proceeds of approximately $56,014. This was a sale (not a purchase) and therefore is not a direct bullish signal; it was executed under a pre-established trading plan.
Key Details
- Transaction date: 2026-04-06 (open market/private sale, code S)
- Price: weighted average $13.43; individual trade prices ranged $13.08–$13.60 (sold in multiple transactions)
- Total shares sold: 4,170; total proceeds ≈ $56,014
- Shares owned after transaction: not reported in the information provided here (check the full Form 4 for beneficial ownership)
- Footnotes: (1) Sale was effected under a 10b5‑1 trading plan adopted Sept 23, 2025. (2) Reported price is a weighted average; the filer can provide per-trade breakdown on request.
- Filing timeliness: Report filed on 2026-04-06 for a 2026-04-06 transaction — no late filing indicated.
Context
Sales under 10b5‑1 plans are typically preplanned and can reflect routine diversification or liquidity needs rather than new information about company prospects. Retail investors should treat this as insider selling data (factual) and not as a standalone signal to buy or sell CTNM shares.
Insider Transaction Report
- Sale
Class A Common Stock
[F1][F2]2026-04-06$13.43/sh−4,170$56,014→ 147,712 total
- 6,842(indirect: By Spouse)
Class A Common Stock
Footnotes (2)
- [F1]These transactions were effected pursuant to a 10b5-1 trading plan adopted by the reporting person on September 23, 2025.
- [F2]The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $13.08 to $13.60, inclusive. The reporting person undertakes to provide to Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote to this Form 4.